Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | -55.56% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.28 | N/A | -55.56% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current performance but highlighted their commitment to addressing operational issues. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future strategies were discussed but lacked specific timelines.
The earnings report indicates that Arrowhead Pharmaceuticals is facing challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 3.12%, likely due to investor concerns about the company's current performance and lack of guidance. Without clear direction from management, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TAKE-TWO INTERACTIVE
Feb 3, 2014